- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07946549
A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
A Dose-escalation and Safety Study of CID-103 Followed by a Randomized, Open-label, Parallel-arm Multi-dose Study Evaluating the Efficacy and Tolerability of CID-103 in Adults With Chronic Immune Thrombocytopenia
The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP). The main questions the study aims to answer are:
- To evaluate the safety and tolerability of CID-103 in subjects with ITP with different increasing doses of CID-103.
- To further evaluate the safety and tolerability of CID-103 at two or three dose levels and to select an optimal dose and administration regimen for CID-103 for further study of clinical efficacy.
The study will be done in two parts:
Part A will test increasing doses of CID-103 to see how safe it is and how well people tolerate it. Researchers will also aim to find a safe dose range.
Part B will compare up to three different doses of CID-103 to see how well the medicine works and gather more safety and efficacy information. The goal is to find the optimal dose to use in future studies.
CID-103 is given through an intravenous (IV) infusion. During the study, participants may receive treatment for up to 6 months, followed by a post-treatment safety follow-up period to check for ongoing safety and effectiveness.This study is an important step toward developing a new treatment for people living with chronic ITP. If CID-103 is found to be safe and effective, it could offer a new option for patients who do not respond well to current therapies.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The enrollment of participants in part A has been completed (ClinicalTrials.gov ID: NCT07017725). Totally 23 participants have been enrolled. Three CID-103 doseages including 600mg, 900mg, and 1200mg have been proposed for part B for further evaluation.
This is Part B study, it will compare 600mg, 900mg, and 1200mg doses of CID-103 to see how well the medicine works and gather more safety and efficacy information. The goal is to find the optimal dose to use in future studies.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Aaron Yang
- Telefonnummer: +86 10 6561 8789
- E-mail: aarony@casi.cn
Undersøgelse Kontakt Backup
- Navn: Hao Zhang
- Telefonnummer: +86 10 6561 8789
- E-mail: haoz@casi.cn
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100000
- Peking Union Medical College Hospital
-
Kontakt:
- Tienan Zhu
- Telefonnummer: +86 10 69151188
- E-mail: zhutn@pumch.cn
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510000
- Nanfang Hospital, Southern Medical University
-
Kontakt:
- Jieyu Ye
- Telefonnummer: +86 20 61641888
- E-mail: jieyu_ye@163.com
-
-
Hebei
-
Tangshan, Hebei, Kina, 063000
- North China University of Science and Technology Affiliated Hospital
-
-
Henan
-
Zhengzhou, Henan, Kina, 450000
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, Kina, 430000
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Kontakt:
- Heng Mei
- Telefonnummer: +86 27 85726114
- E-mail: hmei@hust.edu.cn
-
-
Jiangsu
-
Suzhou, Jiangsu, Kina, 215000
- The First Affiliated Hospital of Soochow University
-
Kontakt:
- Jie Yin
- Telefonnummer: +86 512 65223637
- E-mail: yinjie@suda.edu.cn
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330000
- The First Affiliated Hospital of Nanchang University
-
-
Shaanxi
-
Xi'an, Shaanxi, Kina, 710000
- Shaanxi Provincial People's Hospital
-
Kontakt:
- Yi Wang
- Telefonnummer: +86 29 85251331
- E-mail: 13571936193@163.com
-
-
Shandong
-
Jinan, Shandong, Kina, 50000
- Qilu Hospital of Shandong University
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300000
- Institute of Hematology & Blood Diseases Hospital, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
-
Kontakt:
- Lei Zhang
- Telefonnummer: +86 22 23909999
- E-mail: zhanglei1@ihcams.ac.cn
-
-
Yunnan
-
Kunming, Yunnan, Kina, 650000
- The Second Affiliated Hospital of Kunming Medical University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Male or female individuals aged 18 to 65 years at time of signing of ICF.
-
Diagnosed with ITP that has persisted for ≥ 3 months, diagnosed in accordance with The American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia or the Updated International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia (as locally applicable).
-
Diagnosis of ITP supported by a prior response to an ITP treatment (other than a thrombopoietin receptor agonists [TPO-RA]) that achieved a platelet count of ≥ 30 x 10^9/L and a doubling of baseline measurement.
-
Has received at least two lines of SOC systemic treatment (i.e., corticosteroids and one other agent).
Note: Subjects who have received one line of treatment and who are currently receiving a second line of treatment are also considered eligible Exceptions: Subjects who are intolerant of SOC treatment or subjects who do not have access to SOC treatment; approval from Medical Monitor is required.
-
Has a mean platelet count ≤ 35 x 10^9/L on at least two measurements at least one week apart during screening.
-
If receiving standard background treatment for ITP, treatment should be stable in dose and frequency for at least four weeks prior to first dose of CID-103.
Note: Permitted standard background treatments for ITP may include:
- one oral corticosteroid with or without up to two of the following
- one immunosuppressant from the following list: azathioprine, danazol, dapsone, cyclosporine, mycophenolate mofetil, mycophenolate sodium
- one TPO-RA (romiplostim, eltrombopag, avatrombopag) administered at standard therapeutic doses for at least four weeks
- fostamatinib.
-
Adequate organ function
-
Contraception: Female participants must either be non-pregnant or not breastfeeding and must have a negative pregnancy test. Male and female participants must meet the contraceptive requirements.
Exclusion Criteria:
-
Prior treatment with any anti-CD38 agent, or has been treated with anti-Bruton's tyrosine kinase (BTK), neonatal Fc receptor (FcRn) antagonist or complement inhibitor within three months prior to first dose of CID-103.
-
Use of intravenous (IV) immunoglobulin, subcutaneous immunoglobulin or anti-D immunoglobulin treatment within four weeks of screening.
-
IgG < 300 mg/dL
-
Use or expected immediate use of rescue therapy for an active hemorrhage, high risk of bleeding or critically low platelets within two weeks prior to first dose of CID-103.
-
More than a 10% variation in corticosteroid and/or TPO-RA dose within two weeks prior to first dose of CID-103
-
Treatment with rituximab or splenectomy within the three months prior to first dose of CID-103.
-
Use of anticoagulants or any drug with antiplatelet effect (such as aspirin) within three weeks before screening.
-
Immunosuppressant drugs other than corticosteroids and those outlined in inclusion criterion #6.
Note: These drugs should be discontinued for at least 14 days before first dose of CID-103.
-
Receiving other concurrent investigational therapies or have received investigational therapies within four weeks of the first dose of CID-103 or five half-lives (if shorter).
-
Active hemolytic anemia.
-
Diagnosed with severe chronic obstructive pulmonary disease (COPD), Global Initiative for Chronic Obstructive Lung Disease (GOLD Stage 3 or 4) or asthma, and a pre-bronchodilator forced expiratory volume in one second (FEV1) < 50% of predicted normal.
-
Has been diagnosed with myelodysplastic syndrome or other active malignancy.
-
Known / clinically significant amyloidosis.
-
Requires renal dialysis.
-
Has a history of any thrombotic or embolic event within six months before screening.
-
A history or evidence of cardiovascular risk including any of the following:
- Current left ventricular ejection fraction < 50%
- A history or evidence of current clinically significant uncontrolled ventricular arrhythmia. Subjects with atrial fibrillation controlled for > 30 days prior to first dose of CID-103 are eligible.
- A history of acute coronary syndrome (including myocardial infarction or unstable angina), coronary angioplasty or stenting within six months prior to first dose of CID-103
- A history or evidence of current ≥ Class III congestive heart failure as defined by the New York Heart Association (NYHA) guidelines
- Treatment refractory hypertension defined as a blood pressure of systolic > 160 mmHg and/or diastolic > 100 mmHg which cannot be controlled by anti-hypertensives.
-
History or clinical evidence of any surgical or medical condition which the Investigator judges as likely to interfere with the results of the study or pose an additional risk in participating, particularly any pre-existing condition that would put the subject at additional risk should they experience an IRR
-
Any unresolved treatment-related AE(s) from prior treatment that have not resolved to Grade 1 or baseline value prior to first dose of CID-103.
-
Active infection requiring systemic therapy.
-
Known hypersensitivity to CID-103 excipients or prior severe hypersensitivity to a monoclonal antibody.
-
History of severe recurrent or chronic infections, or acute infections requiring systemic treatment with antibiotics, antiviral drugs, antiparasitic drugs, anti-amoebic drugs, or antifungal drugs within four weeks prior to the first dose of CID-103 and during the screening period, or superficial skin infections requiring systemic treatment within one week prior to the first dose of CID-103.
-
History of known or suspected immunosuppression, including invasive opportunistic infections such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis pneumonia, and aspergillosis, even if the infection has resolved; or unusually frequent, recurrent, or prolonged infections (as judged by the Investigator).
-
Known active infection with human immunodeficiency virus (HIV) and CD4+ T cell count < 350/μL.
-
Known active infection with hepatitis B (HBV) (surface antigen) or infection with hepatitis C (HCV) in absence of sustained virologic response.
-
At the time of signing informed consent is a regular user (including "recreational / medical use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol). If a subject agrees to abstain for the duration of the study and is for a month prior to first dose of CID 103, they may be considered for enrollment in the trial at the discretion of the Investigator in agreement with the Medical Monitor.
-
Karnofsky Performance Status ≤ 70
-
Inability to perform study baseline RBC type and cross-match, phenotype (and genotype, if applicable) or lack of available baseline data on RBC phenotype (or genotype, if applicable).
-
Unable or not willing to agree to the evaluation of RBC antigens by phenotyping or genotyping.
-
Unable or not willing to sign the ICF and comply with the protocol and the restrictions and assessments therein.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: CID-103 1200mg
Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at dose 1200mg administered. |
Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of 6 months. |
|
Eksperimentel: CID-103 900mg
Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at dose 900mg administered. |
Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of 6 months. |
|
Eksperimentel: CID-103 600mg
Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at dose 600mg administered. |
Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of 6 months. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and tolerability of CID-103, Frequency of TEAEs
Tidsramme: 10 months
|
Frequency of TEAEs |
10 months
|
|
Safety and tolerability of CID-103, Related AEs
Tidsramme: 10 months
|
Related AEs |
10 months
|
|
Safety and tolerability of CID-103, Grade 3/4 AEs
Tidsramme: 10 months
|
Grade 3/4 AEs |
10 months
|
|
Safety and tolerability of CID-103, Serious adverse events (SAEs)
Tidsramme: 10 months
|
Serious adverse events (SAEs) |
10 months
|
|
Safety and tolerability of CID-103, Fatal AEs
Tidsramme: 10 months
|
Fatal AEs |
10 months
|
|
Safety and tolerability of CID-103, AEs leading to CID-103 discontinuation
Tidsramme: 12 weeks
|
AEs leading to CID-103 discontinuation up to Week 12 |
12 weeks
|
|
Safety and tolerability of CID-103
Tidsramme: 12 weeks
|
Percentage of participants with at least one treatment-related Grade ≥ 3 TEAE, SAE or AE leading to CID-103 discontinuation up to Week 12 |
12 weeks
|
|
Platelet response
Tidsramme: 12 weeks
|
A platelet count ≥ 50 x 10^9/L and ≥ 20 x 10^9/L above baseline achieved on at least two consecutive measurements at least seven days apart. |
12 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Platelet count
Tidsramme: 12 weeks
|
The secondary efficacy endpoint is Platelet count, defined as platelet count ≥ 30 x 10^9/L and > 2-fold increase in platelet count from baseline and absence of bleeding requiring medical intervention / treatment, measured on at least two consecutive occasions at least seven days apart. |
12 weeks
|
|
Complete platelet response
Tidsramme: 12 weeks
|
The secondary efficacy endpoint includes percentage of participants with complete platelet response, defined as platelet count ≥ 100 x 10^9/L and absence of bleeding requiring medical intervention / treatment, measured on at least two consecutive occasions at least seven days apart. |
12 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studiestol: Junping Chen, CASI pharmaceuticals, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- XY2024067-EC-4
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .